<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38809" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Flutamide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Johnson</surname>
            <given-names>Donavon B.</given-names>
          </name>
          <aff>Ross University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sonthalia</surname>
            <given-names>Sidharth</given-names>
          </name>
          <aff>SKINNOCENCE: The Skin Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Donavon Johnson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sidharth Sonthalia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38809.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Flutamide is used in the management and treatment of androgen-dependent tumors like prostate cancer and conditions associated with hyperandrogenism like polycystic ovarian syndrome (PCOS). It is a prototypical drug of the anti-androgen class of medications. This activity succinctly reviews the indications, action, adverse effects and precautions, and contraindications for flutamide and related congeners as a valuable agent in treating prostate cancer, with a brief description of its use in the treatment in PCOS.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the mechanism of action of flutamide as an anti-androgen drug and discussing its role as a medical therapy in patients with prostate cancer and polycystic ovarian syndrome (PCOS).</p></list-item><list-item><p>Summarize the current evidence regarding flutamide use, efficacy, and safety as a monotherapy and in combination therapy for its indicated purpose.</p></list-item><list-item><p>Identify the other and newer congeners of this anti-androgen group, highlighting the relative advantages and shortcomings of the alternatives.</p></list-item><list-item><p>Outline some interprofessional strategies that can increase the effectiveness of this drug and its congeners to improve patient outcomes and safety.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38809&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38809">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38809.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Flutamide is indicated by the US-FDA for the adult population only to treat stage B2-C and stage D2 metastatic carcinoma of the prostate.<xref ref-type="bibr" rid="article-38809.r1">[1]</xref></p>
        <p>There has been some off-label use for the treatment of hair loss, hirsutism, polycystic ovarian syndrome, and acne. Flutamide has been shown to have fewer side effects in women but continues to have hepatotoxic effects in this population.<xref ref-type="bibr" rid="article-38809.r2">[2]</xref></p>
        <p>In the treatment of acne and seborrhea in women, low-dose flutamide has been shown to&#x000a0;effectively&#x000a0;decrease acne after six months of therapy with peak benefit at one year of use. Other agents have been used in the past for their antiandrogenic effects, such as spironolactone, but flutamide has shown to be the superior antiandrogenic treatment of acne in women, with up to 90% resolution of acne as compared to 40% with spironolactone.</p>
        <p>Flutamide has been effective in treating female pattern hair loss. It can be taken alone or in conjunction with oral birth control in the treatment of hair loss, and this regiment has proven to be superior to cyproterone acetate and finasteride.<xref ref-type="bibr" rid="article-38809.r3">[3]</xref></p>
        <p>In the treatment of hirsutism, flutamide has been demonstrated to have equal or greater effectiveness at treating symptomatology, although it has a risk of hepatic injury compared to other agents such as finasteride, cyproterone acetate, and spironolactone.<xref ref-type="bibr" rid="article-38809.r1">[1]</xref></p>
        <p>First discovered in 1967, its initial&#x000a0;formulation was for use&#x000a0;as an antibiotic. The Schering Plough Corporation of Germany developed and later found it to have antiandrogenic properties. Clinical trials began in 1971,&#x000a0;and&#x000a0;the drug was finally released to the public in 1983 in Germany. In 1989, flutamide received approval from the United States Food and Drug Administration. Flutamide was the first nonsteroidal antiandrogen drug on the market. Other nonsteroidal antiandrogen pharmaceuticals include nilutamide, introduced in 1989, and bicalutamide, in 1995.</p>
      </sec>
      <sec id="article-38809.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Flutamide is a nonsteroidal antiandrogen that competitively binds androgen receptors throughout the body. This binding inhibits cell growth in prostate cancer by inhibiting testosterone&#x02019;s stimulatory effects. The drug has a half-life of 6 hours, meaning dosing will have to occur a minimum of 3 times a day to maintain adequate serum levels. The liver metabolizes flutamide mainly via the CYP3A4 and other cytochrome enzymes such as CYP1A2. Flutamide is primarily excreted in the urine, with less than 5% excreted in the feces.<xref ref-type="bibr" rid="article-38809.r4">[4]</xref></p>
      </sec>
      <sec id="article-38809.s4" sec-type="Administration">
        <title>Administration</title>
        <list list-type="bullet">
          <list-item>
            <p>Flutamide administration is as a&#x000a0;250 mg&#x000a0;oral capsule&#x000a0;given every 8 hours.<xref ref-type="bibr" rid="article-38809.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>For stage B2-C prostatic carcinoma, patients should take flutamide in combination with a gonadotropin-releasing hormone analog that is started eight weeks before the initiation of radiation therapy and continued throughout the course of radiation treatment.<xref ref-type="bibr" rid="article-38809.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Patients should take flutamide for stage D2 metastatic carcinoma of the prostate in combination with a gonadotropin-releasing hormone analog.<xref ref-type="bibr" rid="article-38809.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38809.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Flutamide comes with a black box warning due to the risk of hepatic failure. Hospitalization and death have occurred, although rarely, due to flutamide use; this is due to cholestatic hepatitis, which leads to failure. Cholestatic hepatitis results from the mitochondrial toxicity that occurs due to flutamide's major metabolite, hydroxyflutamide. This metabolite inhibits enzymes that are necessary for the electron transport chain within the mitochondria of the hepatocyte, leading to a halt of cellular respiration and, ultimately, cellular death. Hepatic failure would most likely be evident within the first three months of use. If the hepatic injury does occur in a patient, discontinuation of flutamide may help reverses the injury. Estimates of the rate at which this adverse effect occurs are three persons in 10,000 or 0.03% of all patients who use the drug. Due to this risk, it is advisable to perform liver function tests if symptoms suggest hepatic dysfunction. Such signs to watch for are abdominal pain, anorexia, nausea, vomiting, jaundice, and right upper quadrant pain and tenderness. Recommendations are to discontinue therapy if jaundice develops or if alanine aminotransferase increased to two times the upper limit of normal.<xref ref-type="bibr" rid="article-38809.r7">[7]</xref></p>
        <p>The most common adverse effect of flutamide use is hot flashes, which occur in over 50% of patients. It has also demonstrated a decrease in libido in 36% of the patients taking it. Impotence occurs in 31%.<xref ref-type="bibr" rid="article-38809.r8">[8]</xref><xref ref-type="bibr" rid="article-38809.r9">[9]</xref>&#x000a0;Diarrhea, nausea, and vomiting occur in approximately 1 in 10 patients. Gynecomastia occurs in 9% of patients.<xref ref-type="bibr" rid="article-38809.r10">[10]</xref>&#x000a0;Less common but not rare complications are anorexia, edema, leukopenia, and rash. Rarely hemolytic anemia, methemoglobinemia, along with increased aspartate aminotransferase, alanine aminotransferase, bilirubin, and blood urea nitrogen.<xref ref-type="bibr" rid="article-38809.r11">[11]</xref></p>
        <p>Rarely, flutamide correlates with interstitial pneumonitis that may lead to pulmonary fibrosis, seen in approximately 0.04% of patients.</p>
      </sec>
      <sec id="article-38809.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to flutamide use include patients with a hypersensitivity to flutamide or those with severe hepatic disease.</p>
        <p>It is advised not to concomitantly use flutamide alongside drugs such as idelalisib and ivacaftor, as this will result in serious adverse effects. Idelalisib strongly inhibits the enzyme CYP3A4 in the liver and intestines resulting in increasing the level of flutamide in the body. A metabolite of Ivacaftor, M1, has the same effect potentially if taken with flutamide. Other drugs with similar effects on the CYP3A4 enzyme but with less serious complications are crofelemer, dabrafenib, elvitegravir, cobicistat, emtricitabine, tenofovir, iloperidone, letermovir, and mitotane. These drugs do not necessarily require alternatives, but patients should be monitored closely for adverse effects. Other drugs that come with precautions are teriflunomide, which inhibits CYP1A2 leading to increased levels of flutamide in the serum, and warfarin. Flutamide increases the effects of warfarin, resulting in increased prothrombin time in patients taking both. Other substances to be mindful of when treating a patient with flutamide are maitake and taurine. Maitake is a mushroom with possible antitumor effects, as shown in animal and in-vitro trials. Maitake can increase serum levels of flutamide. Taurine is an organic compound that found its way into popular energy drinks. Flutamide also interacts with taurine, but it is unknown the significance of this interaction.<xref ref-type="bibr" rid="article-38809.r12">[12]</xref></p>
      </sec>
      <sec id="article-38809.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is a risk for severe hepatic injury leading to hepatic failure. There is a potential for aniline toxicity, which may cause methemoglobinemia or hemolytic anemia. The risk of cardiovascular disease may increase due to androgen deprivation.</p>
      </sec>
      <sec id="article-38809.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Flutamide is indicated for the adult population only in the treatment of stage B2-C and stage D2 metastatic carcinoma of the prostate, hyperandrogenic features of PCOS, and few other indications, including&#x000a0;idiopathic hirsutism. The drug may be prescribed by the urologist, oncologist, dermatologist, gynecologist, primary care physician, and nurse practitioner (as per the prevailing laws of the country's healthcare system). However, it is essential that all healthcare workers who prescribe flutamide be aware of the black box warning related to liver failure. Also, the prescribing physician and pharmacist must make sure that the patient is on no other concomitant hepatotoxic medication or a drug that may interfere with its metabolism leading to toxic elevation of serum levels. Thus, at every visit, the patient must be examined and the liver function evaluated. Nursing can also answer patient questions and provide counsel regarding administration and potential adverse effects. It is advised to discontinue therapy if jaundice develops or if alanine aminotransferase increased to two times the upper limit of normal.<xref ref-type="bibr" rid="article-38809.r7">[7]</xref>&#x000a0;Lastly, the treating health personnel should be cognizant of the management principles in case of hepatotoxicity and be aware of similar and newer congeners like bicalutamide, which have better pharmacokinetics and safety profiles. This interprofessional team approach to flutamide therapy can result in improved therapeutic results while minimizing adverse events. [Level 5]</p>
      </sec>
      <sec id="article-38809.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38809&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38809">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38809/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38809">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38809.s10">
        <title>References</title>
        <ref id="article-38809.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachelot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chabbert-Buffet</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Salenave</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kerlan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Galand-Portier</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Anti-androgen treatments.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-24</page-range>
            <pub-id pub-id-type="pmid">20096826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paparodis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dunaif</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Hirsute woman: challenges in evaluation and management.</article-title>
            <source>Endocr Pract</source>
            <year>2011</year>
            <season>Sep-Oct</season>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>807</fpage>
            <page-range>807-18</page-range>
            <pub-id pub-id-type="pmid">21856600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Otoshi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.</article-title>
            <source>Int J Clin Oncol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>848</fpage>
            <page-range>848-856</page-range>
            <pub-id pub-id-type="pmid">30741370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarrabay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hilmi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tinwell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schorsch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pallardy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bars</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rouqui&#x000e9;</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Low dose evaluation of the antiandrogen flutamide following a Mode of Action approach.</article-title>
            <source>Toxicol Appl Pharmacol</source>
            <year>2015</year>
            <month>Dec</month>
            <day>15</day>
            <volume>289</volume>
            <issue>3</issue>
            <fpage>515</fpage>
            <page-range>515-24</page-range>
            <pub-id pub-id-type="pmid">26485406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koss</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Frick</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Activation of androgen receptors protects intact male mice from memory impairments caused by aromatase inhibition.</article-title>
            <source>Horm Behav</source>
            <year>2019</year>
            <month>May</month>
            <volume>111</volume>
            <fpage>96</fpage>
            <page-range>96-104</page-range>
            <pub-id pub-id-type="pmid">30653980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez-Lozano</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;a-Medina</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hansberg-Pastor</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bello-Alvarez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Camacho-Arroyo</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Testosterone Promotes Glioblastoma Cell Proliferation, Migration, and Invasion Through Androgen Receptor Activation.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">30778332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chojnacka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hejmej</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zarzycka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tworzydlo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bilinski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pardyak</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaminska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bilinska</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Flutamide induces alterations in the cell-cell junction ultrastructure and reduces the expression of Cx43 at the blood-testis barrier with no disturbance in the rat seminiferous tubule morphology.</article-title>
            <source>Reprod Biol Endocrinol</source>
            <year>2016</year>
            <month>Mar</month>
            <day>31</day>
            <volume>14</volume>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">27036707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunath</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grobe</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>R&#x000fc;cker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Motschall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Antes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dahm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wullich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meerpohl</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Jun</month>
            <day>30</day>
            <issue>6</issue>
            <fpage>CD009266</fpage>
            <pub-id pub-id-type="pmid">24979481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fransson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Damber</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Klepp</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Foss&#x000e5;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Widmark</surname>
                <given-names>A</given-names>
              </name>
              <collab>Scandinavian Prostate Cancer Group Study 7</collab>
              <collab>Swedish Association for Urological Oncology 3</collab>
            </person-group>
            <article-title>Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>370</fpage>
            <page-range>370-80</page-range>
            <pub-id pub-id-type="pmid">19286422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fagerlund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cormio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Palangi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lewin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Santanelli di Pompeo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Elander</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Selvaggi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Gynecomastia in Patients with Prostate Cancer: A Systematic Review.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>e0136094</fpage>
            <pub-id pub-id-type="pmid">26308532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishizaki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Anraku</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The influence of androgen deprivation therapy on metabolism in patients with prostate cancer.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>657</fpage>
            <page-range>657-60</page-range>
            <pub-id pub-id-type="pmid">15562007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38809.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azarchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bienenfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lo Sicco</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marchbein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nagler</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Androgens in women: Hormone-modulating therapies for skin disease.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>1509</fpage>
            <page-range>1509-1521</page-range>
            <pub-id pub-id-type="pmid">30312645</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
